Malaria drug may boost cancer immunotherapy in advanced melanoma trial
Disease control
Recruiting now
This study tests whether adding hydroxychloroquine (a malaria drug) to standard immunotherapy (nivolumab with or without ipilimumab) can safely improve treatment for advanced melanoma that has spread. About 94 adults with stage III or IV melanoma will take part. The goal is to fi…
Phase: PHASE1, PHASE2 • Sponsor: Ravi Amaravadi, MD • Aim: Disease control
Last updated May 15, 2026 11:54 UTC